Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study

Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study

Abstract Background Novel ADC drugs provide a new therapeutic strategy for gastric cancer.The present study aimed to analyze the clinical efficacy and drug toxicities of disitamab vedotin (RC48) plus immune checkpoint inhibitors(ICIs) and RC48 as third-line therapies and beyond for advanced and meta...

Full description

Bibliographic Details
Main Authors: Caiyun Nie, Weifeng Xu, Yanwei Guo, Xiaohui Gao, Huifang Lv, Beibei Chen, Jianzheng Wang, Yingjun Liu, Jing Zhao, Saiqi Wang, Yunduan He, Xiaobing Chen
Format: Article
Language:English
Published: BMC 2023-12-01
Series:BMC Cancer
Subjects:
Gastric cancer
HER2
Antibody-drug conjugates drugs
RC48
Immunotherapy
Online Access:https://doi.org/10.1186/s12885-023-11735-z

Internet

https://doi.org/10.1186/s12885-023-11735-z

Similar Items